Abstract Library

#4103 The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

Introduction: Tumor evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumors (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease.

Conference:

Presenting Author: Crona J

Authors: Backman S, Botling J, Nord H, Ghosal S, Stålberg P,

Keywords: Pancreatic neuroendocrine tumor, Tumor evolution, Alkylating chemotherapy, Treatment resistance,

#3835 Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine cancer

Introduction: 28% of low-grade neuroendocrine tumors (NETs) present at advanced stages and are unresponsive to therapy, pointing to a gap in our understanding of how these tumors arise and progress.

Conference:

Presenting Author: Dayton T

Authors: Dayton T, Alcala N, Moonen L, den Hartigh L, Mangiante L,

Keywords: Organoids, LCNEC, NET, pulmonary carcinoid, EGF,

#961 Heterogeneity in the Ki-67 Index of Neuroendocrine Tumors

Introduction: Tumor heterogeneity due to tumor evolution is becoming more widely recognised. Neuroendocrine tumors (NET) are routinely graded using the Ki-67 index based on a single tumor location, however, this could lead to undergrading if the Ki-67 index is higher at the metastatic site.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Miller H, Flora R, Drymousis P, Wasan H, Goldin R,

Keywords: tumor heterogeneity, Ki-67,